Home > Insider Trading > Filing (0001144204-18-034653)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1175151	Cytosorbents Corp	CTSO	Surgical & Medical Instruments & Apparatus (3841)	980373793

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1368151	Vincent Capponi	C/O Cytosorbents Corporation 7 Deer Park Drive, Suite K Monmouth Junction NJ 08852	Chief Operating Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2018-06-14	11,367	$3.75	319,350	No	4	M	Direct
Common Stock	Acquisiton	2018-06-15	8,633	$3.75	327,983	No	4	M	Direct
Common Stock	Acquisiton	2018-06-15	40,000	$0.88	367,983	No	4	M	Direct
Common Stock	Disposition	2018-06-14	11,367	$12.00	356,616	No	4	S	Direct
Common Stock	Disposition	2018-06-15	8,633	$12.00	347,983	No	4	S	Direct
Common Stock	Disposition	2018-06-15	15,215	$12.35	332,768	No	4	F	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	F	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2018-06-14	11,367	$0.00	11,367	$3.45
Common Stock	Stock Option (Right to Buy)	Disposition	2018-06-15	8,633	$0.00	8,633	$3.45
Common Stock	Stock Option (Right to Buy)	Disposition	2018-06-15	40,000	$0.00	40,000	$0.88

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
69,933	2010-05-05	2020-05-05	No	4	M	Direct
61,300	2010-05-05	2020-05-05	No	4	M	Direct
0	2011-06-25	2018-06-25	No	4	M	Direct

Footnotes

Stock option exercise and open market sale conducted pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
Includes (i) the following RSUs that will be settled into common stock upon vesting upon a "Change In Control" of the Company: (a) 17,900 RSUs granted on February 24, 2017, (b) 54,000 RSUs granted on June 7, 2016, (c) 125,000 RSUs granted on April 8, 2015 and (d) 10,100 RSUs granted on March 15, 2018 and reported on this Form 4, (ii) the following RSUs subject to vesting as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting: (a) 11,980 of the RSUs granted to the reporting person on February 24, 2017 and unvested as of the date hereof, and (b) 25,334 RSUs granted on February 28, 2018 and unvested as of the date hereof and (iii) 88,454 shares of common stock owned by the reporting person.
These stock options vested at the discretion of the Company's Board of Directors based on satisfying certain criteria including a timely completion of the sepsis trial, raising capital for the Company, and partnering and business development. The options did not vest on May 5, 2010.